Cite
Nelhűbel GA, Cserepes M, Szabó B, et al. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas. Pathol Oncol Res. 2021;27:620256doi: 10.3389/pore.2021.620256.
Nelhűbel, G. A., Cserepes, M., Szabó, B., Türk, D., Kárpáti, A., Kenessey, I., Rásó, E., Barbai, T., Hegedűs, Z., László, V., Szokol, B., Dobos, J., Őrfi, L., & Tóvári, J. (2021). EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas. Pathology oncology research : POR, 27620256. https://doi.org/10.3389/pore.2021.620256
Nelhűbel, Györgyi A, et al. "EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas." Pathology oncology research : POR vol. 27 (2021): 620256. doi: https://doi.org/10.3389/pore.2021.620256
Nelhűbel GA, Cserepes M, Szabó B, Türk D, Kárpáti A, Kenessey I, Rásó E, Barbai T, Hegedűs Z, László V, Szokol B, Dobos J, Őrfi L, Tóvári J. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas. Pathol Oncol Res. 2021 May 03;27:620256. doi: 10.3389/pore.2021.620256. eCollection 2021. PMID: 34257586; PMCID: PMC8262169.
Copy
Download .nbib